Product Code: RP-ID-10094814 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10094814
Market Overview:
Immunoassays in R&D Market Segmentation by Application (Cancer Research, Infectious Diseases, Autoimmune Diseases, Endocrinology, and Others); by End-Use (Academic Laboratories & Institutions, Biotechnology & Pharmaceutical Companies, and Others); and by Product & Services (Analyzers, Software & Services, and Kits & Reagents)-Global Demand Analysis & Opportunity Outlook 2031
Global Immunoassays in R&D Market Highlights Over 2022- 2031
The global immunoassays in the R&D market are estimated to garner a notable revenue by growing at a ~18% CAGR over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to growing cancer, autoimmune disease, infectious disease, endocrine disorders, and other chronic diseases for which immunoassays is used in research and development. As per the World Health Organization, cancer is the leading reason for mortality, and approximately 10 million deaths happened in 2020. An increase in the cancer rate has resulted in more expenditure on cancer research and is expected to increase the growth of the global immunoassays in R&D market. Additionally, environmental problems and an escalate in pollution increase the risk of autoimmune diseases, which require better medication to control the diseases.
GET A SAMPLE COPY OF THIS REPORT
The COVID-19 pandemic had a huge impact on the industry owing to the increased demand from consumers for medical facilities and the decreased supply from suppliers. Furthermore, the healthcare industry was pushed to its greater limit for the COVID- 19 vaccine. Hence, growth in the healthcare industry is anticipated to drive the growth of global immunoassays in the R&D market.
The global immunoassays in the R&D market are segmented by application into cancer research, infectious diseases, autoimmune diseases, endocrinology, and others. Among these segments, the cancer research segment is expected to hold the largest share over the forecast period. The growth of the segment can be attributed to the increase in the cancer rate that requires immunoassays in research and development for earlier diagnosis of cancer and for the development of cancer medicine as well as for estimating the right dosage of the drug that needs to be given to the patient.
Global Immunoassays in R&D Market Regional Synopsis
Regionally, the global immunoassays in the R&D market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of an increase in expenditure on healthcare infrastructure. As per the World Bank, the current health expenditure of China was 3.68% of GDP in 2007 and increased to 5.35% of GDP in 2019. China has undertaken numerous initiatives to build a top-tier research and development infrastructure in the form of the establishment of top universities with strong links to the industrial sector. Furthermore, emerging countries have increased their investment in research and development. Therefore, emerging countries present in the Asia Pacific region is expected to contribute to the growth of the immunoassays in R&D market in the region.
Market Segmentation
Our in-depth analysis of the global immunoassays in R&D market includes the following segments:
By Application
-
Cancer Research
-
Infectious Diseases
-
Autoimmune Diseases
-
Endocrinology
-
Others
By End-Use
-
Academic Laboratories & Institutions
-
Biotechnology & Pharmaceutical Companies
-
Others
By Product & Services
-
Analyzers
-
Software & Services
-
Kits & Reagents
Growth Drivers and Challenges Impacting the Growth of the Global Immunoassays in R&D Market
Growth Drivers
-
Growing concern for the rising prevalence of different types of chronic diseases
-
Increase in the risk of autoimmune diseases owing to environmental pollution
Challenges
-
High cost associated with immunoassays in R&D
-
Lack of regulatory strictness related to research and development
Key Companies Dominating the Global Immunoassays in R&D Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global immunoassays in R&D market that are included in our report are Abbott, Abcam plc, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Sysmex Corporation, Danaher Corporation, bioMérieux, Inc., Becton, Dickinson and Company, Siemens Healthcare GmbH, and others.
Latest Developments in the Global Immunoassays in R&D Market:
-
5 January 2022: Sysmex Corporation has filed an application with Pharmaceuticals and Medical Devices Agency for an assay kit that support in measuring Aβ.
-
9 February 2021: Mindray and Thermo Fisher Scientific Inc., collaborate on clinical chemistry analyzers for use with drugs of abuse immunoassays.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Abbott
- Abcam plc
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd
- Bio-Rad Laboratories, Inc.
- Sysmex Corporation
- Danaher Corporation
- bioMérieux, Inc.
- Becton Dickinson and Company
- Siemens Healthcare GmbH
Related Reports
Proof of Quality & Reliability
